S&P 500   3,347.20 (+0.35%)
DOW   27,638.18 (+0.68%)
QQQ   279.21 (+1.18%)
AAPL   116.44 (+2.06%)
MSFT   210.82 (+1.72%)
FB   263.24 (+0.55%)
GOOGL   1,477.48 (+0.78%)
AMZN   3,164.31 (+0.62%)
TSLA   429.68 (+2.53%)
NVDA   543.13 (+2.67%)
BABA   292.82 (+5.74%)
CGC   14.40 (-0.69%)
MU   47.42 (-6.49%)
GE   6.22 (+1.63%)
AMD   82.54 (+0.94%)
T   28.42 (+0.42%)
F   6.64 (+0.61%)
ACB   4.68 (+0.00%)
GILD   63.01 (+1.47%)
NFLX   500.75 (+1.47%)
DIS   124.35 (-0.84%)
BA   166.27 (+1.63%)
BAC   24.08 (+1.30%)
S&P 500   3,347.20 (+0.35%)
DOW   27,638.18 (+0.68%)
QQQ   279.21 (+1.18%)
AAPL   116.44 (+2.06%)
MSFT   210.82 (+1.72%)
FB   263.24 (+0.55%)
GOOGL   1,477.48 (+0.78%)
AMZN   3,164.31 (+0.62%)
TSLA   429.68 (+2.53%)
NVDA   543.13 (+2.67%)
BABA   292.82 (+5.74%)
CGC   14.40 (-0.69%)
MU   47.42 (-6.49%)
GE   6.22 (+1.63%)
AMD   82.54 (+0.94%)
T   28.42 (+0.42%)
F   6.64 (+0.61%)
ACB   4.68 (+0.00%)
GILD   63.01 (+1.47%)
NFLX   500.75 (+1.47%)
DIS   124.35 (-0.84%)
BA   166.27 (+1.63%)
BAC   24.08 (+1.30%)
S&P 500   3,347.20 (+0.35%)
DOW   27,638.18 (+0.68%)
QQQ   279.21 (+1.18%)
AAPL   116.44 (+2.06%)
MSFT   210.82 (+1.72%)
FB   263.24 (+0.55%)
GOOGL   1,477.48 (+0.78%)
AMZN   3,164.31 (+0.62%)
TSLA   429.68 (+2.53%)
NVDA   543.13 (+2.67%)
BABA   292.82 (+5.74%)
CGC   14.40 (-0.69%)
MU   47.42 (-6.49%)
GE   6.22 (+1.63%)
AMD   82.54 (+0.94%)
T   28.42 (+0.42%)
F   6.64 (+0.61%)
ACB   4.68 (+0.00%)
GILD   63.01 (+1.47%)
NFLX   500.75 (+1.47%)
DIS   124.35 (-0.84%)
BA   166.27 (+1.63%)
BAC   24.08 (+1.30%)
S&P 500   3,347.20 (+0.35%)
DOW   27,638.18 (+0.68%)
QQQ   279.21 (+1.18%)
AAPL   116.44 (+2.06%)
MSFT   210.82 (+1.72%)
FB   263.24 (+0.55%)
GOOGL   1,477.48 (+0.78%)
AMZN   3,164.31 (+0.62%)
TSLA   429.68 (+2.53%)
NVDA   543.13 (+2.67%)
BABA   292.82 (+5.74%)
CGC   14.40 (-0.69%)
MU   47.42 (-6.49%)
GE   6.22 (+1.63%)
AMD   82.54 (+0.94%)
T   28.42 (+0.42%)
F   6.64 (+0.61%)
ACB   4.68 (+0.00%)
GILD   63.01 (+1.47%)
NFLX   500.75 (+1.47%)
DIS   124.35 (-0.84%)
BA   166.27 (+1.63%)
BAC   24.08 (+1.30%)
Log in
OTCMKTS:CTTC

Calmare Therapeutics Stock Forecast, Price & News

$0.09
0.00 (0.00 %)
(As of 09/29/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.09
Now: $0.09
$0.09
50-Day Range
$0.06
MA: $0.08
$0.09
52-Week Range
$0.03
Now: $0.09
$0.20
VolumeN/A
Average Volume14,842 shs
Market Capitalization$2.73 million
P/E RatioN/A
Dividend YieldN/A
Beta0.86
Calmare Therapeutics Incorporated, a medical device company, develops and commercializes products and technologies for chronic neuropathic pain and wound care affliction patients in the United States. Its flagship medical device is Calmare Pain Therapy Device, a non-invasive and non-addictive modality for the treatment of chronic and neuropathic pain. The company was formerly known as Competitive Technologies, Inc. and changed its name to Calmare Therapeutics Incorporated in August 2014. Calmare Therapeutics Incorporated was founded in 1968 and is based in Fairfield, Connecticut.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.38 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:CTTC
CUSIPN/A
Phone203-368-6044

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees7
Market Cap$2.73 million
Next Earnings DateN/A
OptionableNot Optionable
$0.09
0.00 (0.00 %)
(As of 09/29/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CTTC News and Ratings via Email

Sign-up to receive the latest news and ratings for CTTC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Calmare Therapeutics (OTCMKTS:CTTC) Frequently Asked Questions

How has Calmare Therapeutics' stock price been impacted by Coronavirus?

Calmare Therapeutics' stock was trading at $0.0995 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CTTC stock has decreased by 9.8% and is now trading at $0.0897.
View which stocks have been most impacted by COVID-19
.

Who are some of Calmare Therapeutics' key competitors?

What other stocks do shareholders of Calmare Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Calmare Therapeutics investors own include Idera Pharmaceuticals (IDRA), Brainstorm Cell Therapeutics (BCLI), Editas Medicine (EDIT), NVIDIA (NVDA), Shopify (SHOP), Oroplata Resources (ABML), Adobe (ADBE), Advanced Micro Devices (AMD), Activision Blizzard (ATVI) and Yamana Gold (AUY).

Who are Calmare Therapeutics' key executives?

Calmare Therapeutics' management team includes the following people:
  • Mr. Conrad F. Mir, Pres, CEO & Director (Age 50)
  • Mr. Thomas Philip Richtarich M.B.A., Chief Financial Officer (Age 66)
  • Ms. Donna J. Mays, Mang. of Admin. Services
  • Dr. Stephen J. D'Amato, Chief Medical Officer & Member of Medical Advisory Board (Age 71)
  • Mr. William Lipford, Division Head of Product Sales

What is Calmare Therapeutics' stock symbol?

Calmare Therapeutics trades on the OTCMKTS under the ticker symbol "CTTC."

How do I buy shares of Calmare Therapeutics?

Shares of CTTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Calmare Therapeutics' stock price today?

One share of CTTC stock can currently be purchased for approximately $0.09.

How big of a company is Calmare Therapeutics?

Calmare Therapeutics has a market capitalization of $2.73 million. Calmare Therapeutics employs 7 workers across the globe.

What is Calmare Therapeutics' official website?

The official website for Calmare Therapeutics is www.calmaretherapeutics.com.

How can I contact Calmare Therapeutics?

Calmare Therapeutics' mailing address is 1375 KINGS HIGHWAY EAST SUITE 400, FAIRFIELD CT, 06824. The company can be reached via phone at 203-368-6044 or via email at [email protected]

This page was last updated on 9/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.